Global Pricing “Hinders European Arthritis Drug Access”

Many of Europe’s nearly 2 million rheumatoid arthritis patients are still unable to access effective new biologic treatments, and whether they can do so or not is largely dependent on where they live, says a new study…

The largest differences in access are due to a global price for the drugs and large differences in wealth among the 30 nations, says the study.

Read More:

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *